Fig. 5.

DoR, PFS, and OS stratified by predicted C_ave,1stdose and C_{trough,4doses} tertiles for RP2D. Numbers below the plots represent the number of patients at risk at each time point. C_ave,1stdose average concentration during the first treatment dose, C_{trough,4doses} trough concentration after the first four weekly treatment doses (i.e., predose concentration of the fifth weekly treatment dose), DoR duration of response, OS overall survival, PFS progression-free survival, RP2D recommended phase II dose (which is 1.5 mg/kg teclistamab SC administered weekly, with the first treatment dose preceded by step-up doses of 0.06 and 0.3 mg/kg), SC subcutaneous, T1 lowest exposure tertile group, T2 middle exposure tertile group, T3 highest exposure tertile group